The Korean Journal of Internal Medicine This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Genetic susceptibility to post-endoscopic retrograde cholangiopancreatography pancreatitis identified in propensity score-matched analysis
CONCLUSIONS: This study found that the IRF2BP1 gene variant was significantly associated with PEP. This genetic variant is a highly targeted PEP risk factor candidate and can be used for screening high-risk PEP groups before ERCP through future validation. (ClinicalTrials.gov no. NCT02928718).PMID:37867141 | DOI:10.3904/kjim.2022.404 (Source: The Korean Journal of Internal Medicine)
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Young Hoon Choi Younggyun Lim Dong Kee Jang Dong-Won Ahn Ji Kon Ryu Woo Hyun Paik Yong-Tae Kim Ju Han Kim Sang Hyub Lee Source Type: research

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research

Alterations in lung and gut microbiota reduce diversity in patients with nontuberculous mycobacterial pulmonary disease
CONCLUSIONS: Our results reveal that the lung and gut microbiota of patients with NTM-PD exhibit an altered distribution and reduced richness and diversity.PMID:37867139 | DOI:10.3904/kjim.2023.097 (Source: The Korean Journal of Internal Medicine)
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Ji Yeon Choi Bora Shim Youngmok Park Young Ae Kang Source Type: research

Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
CONCLUSIONS: Systemic inflammation, reflected by increased disease activity, may be responsible for the increase in RANKL levels, which causes systemic bone loss in rituximab-treated patients with RA. Although rituximab affects inflammation, it does not seem to alter systemic bone metabolism in RA.PMID:37867140 | DOI:10.3904/kjim.2023.080 (Source: The Korean Journal of Internal Medicine)
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Mie Jin Lim Kyong-Hee Jung Seong-Ryul Kwon Won Park Source Type: research